Table 2.
TAM16 MIC Values for Mtb Strains with Different Drug-Susceptibility Profiles, Related to Tables S4 and S5
| Strain and resistance statusa | Number of strains | MIC90b range for multiple strains (μM) | Median MIC90 (μM) |
|---|---|---|---|
| H37Rv, fully susceptible lab strain | 1 | - | 0.125-0.25 |
| H37RvMa, fully susceptible lab strain | 1 | - | 0.125 |
| Mtb, fully susceptible clinical isolates | 12 | 0.060-0.250 | 0.100 |
| Mtb, poly-resistant clinical isolate | 1 | - | 0.420 |
| Mtb, MDR clinical isolates | 7 | 0.060-0.210 | 0.210 |
| Mtb, pre-XDR clinical isolates | 5 | 0.125-0.420 | 0.420 |
| Mtb, XDR clinical isolates | 5 | 0.125-0.250 | 0.125 |
| Mtb, INH mono-resistant, clinical | 6 | 0.050-0.125 | 0.100 |
| Mtb, RIF mono-resistant, clinical | 1 | - | 0.125 |
| Mtb, SM mono-resistant, clinical | 1 | - | 0.420 |
Poly-resistant, Mtb-strain resistant to isoniazid (INH), ethionamide, and streptomycin (SM); MDR, resistant to both INH and rifampicin (RIF), with or without resistance to other anti-TB drugs; pre-XDR, MDR strains with additional resistance to either a fluoroquinolone or an injectable but not both; XDR, MDR strains that are also resistant to any fluoroquinolone and to any of the three second-line injectables (amikacin, capreomycin, and kanamycin).
Detailed description of the strains with their drug-resistance phenotypes is given in Tables S4 and S5.
The lowest concentration of drug that inhibited growth of more than 90% of the bacterial population was considered to be the MIC90. The MIC90 values were determined using MGIT 960 system.